| CAS No.: | 2381089-83-2 |
|---|---|
| Formula: | C50h69n15o9 |
| EINECS: | 1308068-626-2 |
| Type: | Pharmaceutical Intermediates |
| Appearance: | Powder |
| Quality: | Technical |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
MOTS-c, a 16 amino acid mitochondrial derived peptide, is encoded from the 12S rRNA region of the mitochondrial genome. Under stress conditions, MOTS-c translocates to the nucleus where it regulates a wide range of genes in response to metabolic dysfunction. It is colocalized to mitochondria in various tissues and is found in plasma, but the levels decline with age. Since MOTS-c has important cellular functions as well as a possible hormonal role, it has been shown to have beneficial effects on age-related diseases including Diabetes, Cardiovascular diseases, Osteoporosis, postmenopausal obesity and Alzheimer. Aging is characterized by gradual loss of (mitochondrial) metabolic balance, decreased muscle homeostasis and eventual diminished physical capability, which potentially can be reversed with MOTS-c treatment. This review examines the latest findings on biological effects of MOTS-c as a nuclear regulatory peptide and focuses on the role of MOTS-c in aging and age-related disorders, including mechanisms of action and therapeutic potential.
You Get What You Paid For :
| 2mg | 5mg | 10mg | |
| Semaglutide | $70/Box | $120/Box | $210/Box |
| Tirzepatide | $85/Box | $130/Box | $240/Box |
| Retatrutide | $125/Box | $220/Box | $370/Box |
It's in US Dollar, 10vials per Box. Price is negotiated if order in bulk. Good quality with after-sale
service superior to peers.
Purchasing objects are required to be companies and labs, not for personal use.
Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists,
or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating. One role of GLP-1 is to
prompt the body to produce more isulin, which reduces blood sugar (glucose).
Tirzepatide FDA Approves New Medication for Chronic Weight Management.Tirzepatide (Mounjaro) is used for weight loss and type 2 diabetes in adults. Tirzepatide is a GIP and GLP-1 receptor agonist and works for weight loss by
decreasing your appetite and slowing the movement of food from the stomach into the small intestine, which may make
you feel full more quickly and for a longer period of time. Tirzepatide also decreases blood sugar levels by increasing
isulin production and lowering the amount of sugar the liver makes.
Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus, obstructive sleep
apnea, osteoarthritis, obesity and non-alcoholic fatty liver disease. The drug candidate is administered through
subcutaneous and intravenous route. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1),
glucose-dependent isulinotropic polypeptide (GIP), and glucagon receptors. It is a new molecular entity.
All Peptides For Research Purpose Only, abuse is prohibited.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}